Yosemite, which funds startups and researchers focused on the disease, is targeting a total of $350 million for its second fund from high-powered investors like pharma giant Amgen and hospital ...
In Voges, I see a success story that hasn’t been loud or flashy. It has been methodical, modern and deeply effective.